{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:49:19Z","timestamp":1791485359521,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Real-world data regarding subcutaneous infliximab (SC-IFX) in patients with pediatric inflammatory bowel disease IBD (PIBD) is scarce. We evaluated SC-IFX as maintenance therapy in PIBD patients who switched to SC-IFX from intravenous infliximab (IV-IFX) treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective multicenter study we identified PIBD patients who switched to SC-IFX. The primary outcome was treatment persistence at up to 12\u2009months post-switch. Secondary outcomes included relapse rate (defined as Pediatric Ulcerative Colitis Activity Index [PUCAI] \u2009\u226510\/ weighted PCDAI\u2009 \u2265 12.5 with biochemical\/endoscopic evidence of disease activity), IFX trough levels, immunogenicity, safety, and acceptance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-six patients switched to SC-IFX (48% males; median switch-age, 16.5\u2009years; IQR, 14.9-17.3 years; median switch-weight, 60\u2009kg; range, 13-102\u2009kg), 41\/66 (62%) with Crohn Disease. Pre-switch, the median IV-IFX maintenance dose was 10\u2009mg\/kg every 6 weeks; 58\/66 patients (88%) were in clinical remission. The initial SC-IFX regimen was 120\u2009mg every other week in 62\/66 patients (94%). SC-IFX persistence was 78% (95% CI, 66-91) at 12\u2009months post-switch, with 89% of patients persisting on IFX, either intravenous (IV) or subcutaneous (SC), at the end of follow-up. Relapses were observed in 11\/66 patients (17%) over a median follow-up of 11.0\u2009months (IQR, 5.1-12.0); 6 patients underwent SC-IFX dose intensification, with 3 successfully regaining clinical response. Regarding anti-drug antibodies (ADA), 3 out of 4 patients who were ADA positive on IV-IFX resolved post-switch. Overall, 19\/66 patients (29%) reported 21 adverse events (AEs), including 3\/21 severe AEs. The majority (53\/66 patients; 80%) expressed a positive attitude toward SC-IFX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The largest documented PIBD cohort switching to SC-IFX to date showed high treatment persistence at 1\u2009year, confirming SC-IFX as an effective and safe maintenance alternative to IV-IFX.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf335","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:57:24Z","timestamp":1766581044000},"page":"1086-1096","source":"Crossref","is-referenced-by-count":5,"title":["Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6215-8443","authenticated-orcid":false,"given":"Esm\u00e9e Helen","family":"Boute","sequence":"first","affiliation":[{"name":"Department of Paediatric Gastroenterology, Erasmus Medical Centre Sophia Children\u2019s Hospital , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gianolio","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Royal Hospital for Children and Young People , Edinburgh,","place":["Scotland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaden","family":"Mahmmod","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Erasmus Medical Centre Sophia Children\u2019s Hospital , Rotterdam,","place":["The Netherlands"]},{"name":"Department of Paediatrics, University Medical Centre Utrecht, Utrecht University , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Pochesci","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Royal Hospital for Children and Young People , Edinburgh,","place":["Scotland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Royal Hospital for Children and Young People , Edinburgh,","place":["Scotland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3634-6428","authenticated-orcid":false,"given":"Paul","family":"Henderson","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Royal Hospital for Children and Young People , Edinburgh,","place":["Scotland"]},{"name":"Child Life and Health, Centre of Inflammation Research, University of Edinburgh , Edinburgh,","place":["Scotland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Charles","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Royal Hospital for Children and Young People , Edinburgh,","place":["Scotland"]},{"name":"Child Life and Health, Centre of Inflammation Research, University of Edinburgh , Edinburgh,","place":["Scotland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissy","family":"de Ridder","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Erasmus Medical Centre Sophia Children\u2019s Hospital , Rotterdam,","place":["The Netherlands"]},{"name":"Department of Paediatrics, Willem-Alexander Children\u2019s Hospital\/Leiden University Medical Centre , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Kay","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Royal Hospital for Children and Young People , Edinburgh,","place":["Scotland"]},{"name":"Child Life and Health, Centre of Inflammation Research, University of Edinburgh , Edinburgh,","place":["Scotland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna Caroline","family":"Escher","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Erasmus Medical Centre Sophia Children\u2019s Hospital , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"2026060322320282600_izaf335-B1","author":"European Medicines Agency"},{"key":"2026060322320282600_izaf335-B2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update","volume":"15","author":"van Rheenen","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026060322320282600_izaf335-B3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/jpn3.70097","volume-title":"J Pediatr Gastroenterol Nutr","author":"Wine","year":"2025"},{"key":"2026060322320282600_izaf335-B4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40271-014-0075-y","article-title":"Intravenous versus subcutaneous drug administration. which do patients prefer? A systematic review","volume":"8","author":"Stoner","year":"2014","journal-title":"Patient"},{"key":"2026060322320282600_izaf335-B5","author":"European Medicines Agency","year":"2020"},{"key":"2026060322320282600_izaf335-B6","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"2026060322320282600_izaf335-B7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40261-023-01252-z","article-title":"Subcutaneous infliximab monotherapy versus combination therapy with immunosuppressants in inflammatory bowel disease: a post hoc analysis of a randomised clinical trial","volume":"43","author":"D\u2019Haens","year":"2023","journal-title":"Clin Drug Investig"},{"key":"2026060322320282600_izaf335-B8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre cohort study","volume":"16","author":"Smith","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026060322320282600_izaf335-B9","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026060322320282600_izaf335-B10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s10620-025-08876-5","article-title":"Switching to subcutaneous infliximab maintenance therapy is effective in patients with inflammatory bowel disease","volume":"70","author":"Rautakorpi","year":"2025","journal-title":"Dig Dis Sci"},{"key":"2026060322320282600_izaf335-B11","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.cgh.2025.04.028","article-title":"PErsistence and safety of subcutaneous infliximab 1 year after switch from intravenous route in IBD patients in REMission","volume":"23","author":"Mathieu","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026060322320282600_izaf335-B12","doi-asserted-by":"publisher","first-page":"100588","DOI":"10.1016\/j.gastha.2024.11.004","article-title":"A comparison of intravenous infliximab versus subcutaneous infliximab on remission rates, safety, costs, patient preferences in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"4","author":"Nieto Dominguez","year":"2025","journal-title":"Gastro Hep Adv"},{"key":"2026060322320282600_izaf335-B13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/eci.14283","article-title":"An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study","author":"D\u2019Amico","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"2026060322320282600_izaf335-B14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"2026060322320282600_izaf335-B15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.dld.2024.09.015","article-title":"Persistence of subcutaneous versus intravenous infliximab in a real-life cohort: a propensity-score matched comparative analysis","volume":"57","author":"Bothorel","year":"2025","journal-title":"Dig Liver Dis"},{"key":"2026060322320282600_izaf335-B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/ecco-jcc\/jjae127","article-title":"Subcutaneous infliximab cutoff points in patients with inflammatory bowel disease: data from the ENEIDA registry","volume":"19","author":"Iborra","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026060322320282600_izaf335-B17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/ibd\/izad094","article-title":"One-year clinical outcomes of subcutaneous infliximab maintenance therapy compared with intravenous infliximab maintenance therapy in patients with inflammatory bowel disease: a prospective cohort study","volume":"30","author":"Hong","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026060322320282600_izaf335-B18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/apt.70267","article-title":"Meta-analysis: intravenous versus subcutaneous infliximab in inflammatory bowel disease","volume":"62","author":"Chetwood","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026060322320282600_izaf335-B19","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s00431-020-03750-0","article-title":"Infliximab in young paediatric IBD patients: it is all about the dosing","volume":"179","author":"Jongsma","year":"2020","journal-title":"Eur J Pediatr"},{"key":"2026060322320282600_izaf335-B20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MPG.0000000000003838","article-title":"Effectiveness of switching to subcutaneous infliximab in pediatric inflammatory bowel disease patients on intravenous maintenance therapy","volume":"77","author":"Gianolio","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026060322320282600_izaf335-B21","doi-asserted-by":"publisher","first-page":"102680","DOI":"10.1016\/j.clinre.2025.102680","article-title":"A series of pediatric patients with inflammatory bowel disease switching from intravenous to subcutaneous infliximab maintenance therapy","volume":"49","author":"Duquerois","year":"2025","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2026060322320282600_izaf335-B22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","article-title":"ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents","volume":"58","author":"Levine","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026060322320282600_izaf335-B23","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2026060322320282600_izaf335-B24","doi-asserted-by":"publisher","first-page":"615216","DOI":"10.3389\/fped.2021.615216","article-title":"An overview of tools to score severity in pediatric inflammatory bowel disease","volume":"9","author":"Shaoul","year":"2021","journal-title":"Front Pediatr"},{"key":"2026060322320282600_izaf335-B25","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.3390\/biomedicines10092130","article-title":"Subcutaneous infliximab [CT-P13], a true biologic 2.0. real clinical practice multicentre study","volume":"10","author":"Huguet","year":"2022","journal-title":"Biomedicines"},{"key":"2026060322320282600_izaf335-B26","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000002228","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: an individual participant data meta-analysis","author":"Cummings","journal-title":"J Clin Gastroenterol"},{"key":"2026060322320282600_izaf335-B27","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1093\/ibd\/izaf172","article-title":"When to switch to subcutaneous infliximab? The RE-WATCH multicenter study","volume":"31","author":"Bertani","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026060322320282600_izaf335-B28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.20524\/aog.2023.0816","article-title":"Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience","volume":"36","author":"Jeffrey","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"2026060322320282600_izaf335-B29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cgh.2025.03.021","article-title":"Immunogenicity and efficacy of subcutaneous infliximab monotherapy vs combination therapy in inflammatory bowel disease: a systematic review and meta-analysis","volume":"24","author":"Anjie","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026060322320282600_izaf335-B30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S2468-1253","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026060322320282600_izaf335-B31","doi-asserted-by":"publisher","first-page":"jjaf151","DOI":"10.1093\/ecco-jcc\/jjaf151","article-title":"Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics-pharmacodynamics study","volume":"19","author":"Wang","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026060322320282600_izaf335-B32","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cgh.2023.09.027","article-title":"Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with inflammatory bowel disease suffering from obesity: a post hoc analysis of the REMSWITCH study","volume":"22","author":"Buisson","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026060322320282600_izaf335-B33","doi-asserted-by":"publisher","first-page":"i1921","DOI":"10.1093\/ecco-jcc\/jjad212.1204","article-title":"P1074 impact of body mass index (BMI) on clinical outcomes and drug levels in patients with Crohn\u2019s disease receiving maintenance treatment with subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD study","volume":"18","author":"Yarur","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026060322320282600_izaf335-B34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13318-025-00959-y","article-title":"Simulated dosing regimens of subcutaneous infliximab in adults and children with inflammatory bowel disease: exploring switch and initiation strategies","volume":"50","author":"Weersink","year":"2025","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2026060322320282600_izaf335-B35","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/MPG.0000000000002631","article-title":"Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations","volume":"70","author":"Winter","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026060322320282600_izaf335-B36","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.3390\/jcm11206173","article-title":"Therapeutic drug monitoring of subcutaneous infliximab in inflammatory bowel disease\u2014understanding pharmacokinetics and exposure response relationships in a new era of subcutaneous biologics","volume":"11","author":"Little","year":"2022","journal-title":"J Clin Med"},{"key":"2026060322320282600_izaf335-B37","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/ecco-jcc\/jjad188","article-title":"Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease","volume":"18","author":"Roblin","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026060322320282600_izaf335-B38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/apt.16852","article-title":"Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn\u2019s disease","volume":"56","author":"Roblin","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026060322320282600_izaf335-B39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00384-024-04727-3","article-title":"Subcutaneous infliximab in Crohn\u2019s disease patients with previous immunogenic failure of intravenous infliximab","volume":"39","author":"Husman","year":"2024","journal-title":"Int J Colorectal Dis"},{"key":"2026060322320282600_izaf335-B40","doi-asserted-by":"publisher","first-page":"otaf008","DOI":"10.1093\/crocol\/otaf008","article-title":"Barriers, drivers, and outcomes in transitioning patients with inflammatory bowel disease from intravenous to subcutaneous infliximab","volume":"7","author":"Campion","year":"2025","journal-title":"Crohns Colitis 360"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/6\/1086\/66677014\/izaf335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/6\/1086\/66677014\/izaf335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:32:18Z","timestamp":1780540338000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/6\/1086\/8450262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,1]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf335","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,2,1]]}}}